UCSD Antiviral Research Center CRS*

San Diego, California 92103

1 studies enrolling now · 27 studies all time

What they study most

COVID-19, Cardiovascular Diseases, Covid19, HIV, HIV Infection, HIV Infections, HIV-1, HIV-1-infection, Hepatitis C, Hepatitis C Infection, Liver Disease, MPOX

Studies at this site

• Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV — Paused
• The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE — Running, not enrolling
• Study of Tecovirimat for Human Mpox Virus — Stopped early
• A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection — Starting soon
• Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy — Paused
• Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults — Completed
• Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 — Completed
• Pharmacokinetics and Safety of SAR441236 — Stopped early
• SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine — Completed
• Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND) — Completed
• Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART — Stopped early
• Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 — Stopped early
• Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV) — Completed
• Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults — Completed
• Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART) — Completed
• Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection — Completed
• Optimizing Treatment for Treatment-Experienced, HIV-Infected People — Completed
• Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults — Completed
• Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women — Completed
• Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects — Completed
• Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB) — Completed
• Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women — Completed
• Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients — Completed
• Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications — Completed
• Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals — Completed
• Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF) — Completed
• Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women — Completed